Agomab's Ontunisertib Shows 3% Event Rate in Crohn's Fibrosis Extension Study
AGMB sits 27% above its 52-week low of $8.75.
Summary
Agomab reported positive 48-week open-label extension data for ontunisertib in fibrostenosing Crohn's disease. The annualized FSCD-related event rate was just 3% with only one endoscopic balloon dilation and no surgeries over up to 60 weeks, versus 23-35% in comparable populations on advanced therapies. Safety and tolerability remained favorable with no cardiac, liver, or thrombotic signals. These results support initiation of the global NOV-ERA Phase 2b study in the coming months. This is the first efficacy signal for ontunisertib in this indication and materially de-risks the program.
At the time of this announcement, AGMB was trading at $11.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $546.7M. The 52-week trading range was $8.75 to $17.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.